Clinical practice guideline for multi-disciplinary team diagnosis and treatment of stage Ⅳ primary lung cancer in China.
10.3760/cma.j.cn112152-20211221-00959
- VernacularTitle:中国Ⅳ期原发性肺癌多学科团队诊疗实施指南
- Collective Name:Chinese Association for Clinical Oncologists;Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare
- Publication Type:Journal Article
- Keywords:
Guideline;
Lung neoplasms;
Multi-disciplinary treatment
- MeSH:
China;
Humans;
Lung Neoplasms/therapy*;
Neoplasm Staging;
Patient Care Team;
Practice Guidelines as Topic
- From:
Chinese Journal of Oncology
2022;44(7):667-672
- CountryChina
- Language:Chinese
-
Abstract:
Although there are many treatment options for patients with stage Ⅳ primary lung cancer, the problems in the diagnosis and treatment process may involve multiple systems and organs due to their complex condition and heterogeneity. Therefore, cooperation between different disciplines is often required in the process of clinical practice. Multi-disciplinary team (MDT) refers to a fixed working group composed of more than two related disciplines, which puts forward the best treatment strategy for individual patient in the form of regular consultation for a certain system disease, and then the related disciplines implement the treatment strategy alone or jointly. MDT is widely used for disease diagnosis and treatment, and especially suitable for cancer patients. MDT has become a standard procedure for cancer treatment worldwide, including stage Ⅳ primary lung cancer. In order to promote the healthy development of MDT and generally improve the level of diagnosis and treatment of stage Ⅳ primary lung cancer in China, Chinese Association for Clinical Oncologists and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare co-organized the national experts committee to formulate "Clinical practice guideline for multi-disciplinary team diagnosis and treatment of stage Ⅳ primary lung cancer in China" .
